Where does Kush M Parmar work?

Kush M Parmar is Managing Partner at 5AM Ventures and Board director at Ensoma and Board director at Akouos and Board director at Entrada Therapeutics, Inc..

What does Kush M Parmar invest in?

Kush M Parmar invests in Biotech, Healthtech, Medical Devices.

What check size does Kush M Parmar write?

Kush M Parmar typically writes checks of $100K – $5M.

What boards does Kush M Parmar sit on?

Kush M Parmar holds tracked board seats at Akouos, Ensoma, Entrada Therapeutics, Inc., Rallybio, LLC.

Where did Kush M Parmar go to school?

Kush M Parmar studied at Harvard Medical School (MD); Harvard Business School (Finance); Massachusetts Institute of Technology (M.D., HST Program).

Kush M Parmar

Investor

Managing Partner at 5AM Ventures · Board director at Ensoma · Board director at Akouos · Board director at Entrada Therapeutics, Inc.

Boston, Massachusetts

Writes $100K – $5M checks · typically $1.5M

Kauffman Fellow · Class 16

Find your path to Kush

1,414 people in our graph share verified history with Kush — schools, employers, funds. One of them is your warm intro.

Kyle DohertyunlockedKush: together at Massachusetts Institute of Technology (2002–2004)

Kush: together at 5AM Ventures

×3Kush: together at Harvard Medical School

×4Kush: together at Harvard University

About

Kush Parmar combines a Harvard M.D./Ph.D.-backed technical rigor with a cross‑border US–India perspective, taking hands‑on roles as co‑founder, chair, or senior executive to build globally relevant biotech, including India-focused initiatives.

Contact· self-published, not guessed

k•••@5amventures.comreveal

Likely emails· guessed from name + firm domain, not firm-published

k•••@5amventures.comreveal100% confident
k•••@5amventures.comreveal75% confident

Invests in

BiotechHealthtechMedical Devices

Board director at Ensoma

Intro paths

→

In turn, Kush can intro founders to Ensoma's investors below.

Ensoma's investors · 14

5AM VenturesBoston · $100K – $4M checks · since 2023 Aju IB Invesment CorporationSeoul · since 2021 AlexandriaPasadena · since 2023 Arix BioscienceLondon · since 2023 Bill & Melinda Gates FoundationSeattle · since 2023 Bioluminescence VenturesSan Francisco · since 2023 Catalio Capital ManagementNew York · since 2023 Catalio Capital Management, LPNew York · since 2021 Delos CapitalCambridge · since 2023 F-Prime CapitalCambridge · $3M – $10M checks · since 2023 Solasta VenturesBoston · since 2023 SymBiosisBentonville · since 2023 Takeda VenturesCambridge · $1M – $5M checks · since 2023 Viking Global InvestorsStamford · since 2023

Board director at Akouos

Intro paths

→

In turn, Kush can intro founders to Akouos's investors below.

Akouos's investors · 8

5AM VenturesBoston · $100K – $4M checks · since 2018 Cowen Healthcare InvestmentsNew York EcoR1 CapitalSan Francisco Fidelity InvestmentsBoston New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks · since 2017 Pivotal Life SciencesSan Francisco RA CapitalBoston Sofinnova VenturesMenlo Park · $100K – $15M checks

Co-founders at Akouos

Emmanuel SimonsExecutive Officer, Director

william sewellFounder

Board director at Entrada Therapeutics, Inc.

Intro paths

→

In turn, Kush can intro founders to Entrada Therapeutics, Inc.'s investors below.

Entrada Therapeutics, Inc.'s investors · 6

5AM VenturesBoston · $100K – $4M checks · since 2021 Agent CapitalWaltham MPM BioImpactBoston · $1M – $15M checks · since 2021 MRL Ventures FundCambridge · $25M checks Roche Venture FundBasel · $648K – $3.2M checks TCG CrossoverPalo Alto

Experience

5AM VenturesManaging Partnercurrent2010 — presentBoston, MA
Harvard Medical SchoolBoard of Fellowscurrent2025 — present
ProLynxChairmancurrent2025 — present
Precede BiosciencesChairmancurrent2021 — present
GlycoEra AGBoard Membercurrent2021 — present
Entrada TherapeuticsChairman Of The Board Of Directorscurrent2016 — present
EnsomaBoard Membercurrent2019 — presentBoston, Massachusetts, United States
Immuneel Therapeutics, Ltd.Co-Foundercurrent2019 — presentBangalore, India
Princeton UniversityAdvisory Council, Department of Molecular Biologycurrent2015 — presentPrinceton, NJ
Audentes TherapeuticsBoard Of Directorscurrent2013 — present
Homology Medicines, Inc.Founding CEO, Chairman2015 — 2023Boston, Massachusetts
Vor BiopharmaChairman2019 — 2022
AkouosBoard Of Directors2017 — 2022Greater Boston
ArvinasBoard of Directors2013 — 2019
scPharmaceuticalsBoard of Directors2014 — 2018
Novira TherapeuticsBoard Observer and Acting VP, Strategy and Corporate Development2012 — 2015
AchaogenBoard Observer2010 — 2014
Society of Kauffman FellowsKauffman Fellow, Class 162011 — 2013
Envoy Therapeutics, Inc.Board Observer2010 — 2012
Cruz Blanca InitiativeFounder, President2000 — 2010

Skills & more

Lifesciences29Start-ups12Drug Discovery43Corporate Development13Strategy28Cancer4Oncology9Venture Capital57Clinical Development6Entrepreneurship16Business Development8Commercialization9

+6 more

Life SciencesPharmaceutical IndustryPrivate EquityBiotechnologyCellTechnology Transfer

From Kush's professional profile.

Deals · 2

Entrada Therapeutics, Inc.Board seat

via 5AM Ventures · filed Apr 2021 · $116.2M raise

AkouosBoard seat

via 5AM Ventures · filed Aug 2018 · $50.1M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Ensoma Rallybio, LLC

Investor

ArvinasAudentes TherapeuticsCleave TherapeuticsEnsoma PrecedeProlynxVor Biopharma

Sources: SEC Form D filings · curated public sources.

Colleagues at 5AM Ventures

Alex Wareham

Management Company Controller at 5AM Ventures

Andy Schwab

Managing Partner at 5AM Ventures

Aniqa Tasnim

Senior Associate at 5AM Ventures

Anna Yaeger

Chief Investment Officer and Partner at 5AM Ventures

Arthur Tzianabos

Venture Partner at 5AM Ventures

Bella Nittolo

Administrative Assistant and Office Manager at 5AM Ventures

Brian Daniels

Venture Partner at 5AM Ventures

Caroline Chamales

Senior Executive Assistant at 5AM Ventures

Network2

Mira ChaurushiyaMentee

Managing Director at Westlake Village BioPartners

Scott RocklageMentor

Managing Partner at 5AM Ventures with over 20 years of healthcare management experience

Investors connected to Kush in public investor directories — a warm-intro map.

Frequently asked questions

Who is Kush M Parmar?: Kush Parmar combines a Harvard M.D./Ph.D.-backed technical rigor with a cross‑border US–India perspective, taking hands‑on roles as co‑founder, chair, or senior executive to build globally relevant biotech, including India-focused initiatives.
Where does Kush M Parmar work?: Kush M Parmar is Managing Partner at 5AM Ventures and Board director at Ensoma and Board director at Akouos and Board director at Entrada Therapeutics, Inc..
What does Kush M Parmar invest in?: Kush M Parmar invests in Biotech, Healthtech, Medical Devices.
What check size does Kush M Parmar write?: Kush M Parmar typically writes checks of $100K – $5M.
What boards does Kush M Parmar sit on?: Kush M Parmar holds tracked board seats at Akouos, Ensoma, Entrada Therapeutics, Inc., Rallybio, LLC.
What companies has Kush M Parmar invested in?: Investments tracked here include Akouos, Arvinas, Audentes Therapeutics, Cleave Therapeutics, Ensoma, Precede, Prolynx, Vor Biopharma.
Where did Kush M Parmar go to school?: Kush M Parmar studied at Harvard Medical School (MD); Harvard Business School (Finance); Massachusetts Institute of Technology (M.D., HST Program).